79/100
✓ Peer-reviewed
alzhub usefulness score 79 out of 100.
·
JAMA neurology
·
2023-04-01
Among 171 Aβ-positive CU participants included in the main analyses, 119 (mean [SD] age, 73.0 [5.4] years; 60.5% female) were from the BioFINDER-1 study, and 52 (mean [SD] age, 64.4 [4.6] years; 65.4% female) were from the WRAP study. 2 key findings →
Design: cohort study
Participants: 564
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Although recent clinical trials targeting amyloid-β in Alzheimer's disease have shown promising results, there is increasing evidence suggesting that understanding alternative disease pathways that interact with amyloid-β metabolism and amyloid pathology might be important to halt the clinical deterioration. 4 key findings →
Design: longitudinal study
Participants: 75
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
76/100
✓ Peer-reviewed
alzhub usefulness score 76 out of 100.
·
JAMA neurology
·
2019-07-01
The NfL level was increased at baseline in patients with mild cognitive impairment and AD dementia (mean levels: cognitive unimpairment, 32.1 ng/L; mild cognitive impairment, 37.9 ng/L; and AD dementia, 45.9 ng/L; P Conclusions and relevance The findings suggest that plasma NfL can be used as a noninvasive biomarker associated with neurodegeneration in patients with AD and may be useful to monitor effects in trials of disease-modifying drugs. 3 key findings →
Design: cohort study
Participants: 1,583
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
74/100
✓ Peer-reviewed
alzhub usefulness score 74 out of 100.
·
Neurology
·
2016-09-30
Plasma tau partly reflects AD pathology, but the overlap between normal aging and AD is large, especially in patients without dementia. 3 key findings →
Design: longitudinal study
Participants: 179
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Smoothing splines demonstrated that earliest plasma p-tau181 changes occurred even before amyloid-β markers reached abnormal levels, with greater rates of change correlating with increased amyloid-β pathology. 4 key findings →
Design: prospective cohort
Participants: 1,067
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
73/100
✓ Peer-reviewed
alzhub usefulness score 73 out of 100.
·
Neurology
·
2018-07-27
Neuroinflammation and cerebrovascular dysfunction are early events occurring already at presymptomatic stages of AD and contribute to disease progression. 5 key findings →
Design: longitudinal study
Participants: 508
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
72/100
✓ Peer-reviewed
alzhub usefulness score 72 out of 100.
·
Neurology
·
2015-09-09
The best CSF measures for identifying MCI-AD were Aβ42/total tau (t-tau) and Aβ42/hyperphosphorylated tau (p-tau) (area under the curve [AUC] 0.93-0.94). 3 key findings →
Design: longitudinal study
Participants: 122
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
71/100
✓ Peer-reviewed
alzhub usefulness score 71 out of 100.
·
Neurology
·
2018-04-13
The prevalence of pathologic AD markers was very common (46%) in a representative population sample of 70-year-olds. 3 key findings →
Design: cohort study
Participants: 322
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
70/100
✓ Peer-reviewed
alzhub usefulness score 70 out of 100.
·
Neurology
·
2017-12-01
Increased levels of triglycerides at midlife predict brain Aβ and tau pathology 20 years later in cognitively healthy individuals. 5 key findings →
Design: cohort study
Participants: 134
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Baseline plasma GFAP could detect abnormal CSF Aβ42/40 and CSF Aβ42/T-tau with an AUC of 0.79 (95% CI 0.72-0.86) and 0.80 (95% CI 0.72-0.86), respectively. 3 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
Neurology
·
2023-05-24
In a community-based cohort of 70-year olds, P-NfL was associated with both prevalent and incident CKD, while CSF and/or imaging measures did not differ by CKD status. 3 key findings →
Design: cohort study
Participants: 744
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
Neurology
·
2024-06-03
Our study suggests a possible utility of plasma Aβ42/40, P-tau181, and P-tau231 as a noninvasive biomarkers to assess amyloid copathology in DLB, and plasma GFAP and NfL as monitoring biomarkers for cognitive symptoms in DLB. 4 key findings →
Design: cohort study
Participants: 89
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
Nature aging
·
2023-05-18
Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD) in clinical practice. 5 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
67/100
✓ Peer-reviewed
alzhub usefulness score 67 out of 100.
·
JAMA neurology
·
2016-01-01
Cerebrospinal fluid NFL concentration (median [interquartile range]) was higher in the AD dementia group (1479 [1134-1842] pg/mL), stable MCI group (no progression to AD during follow-up; 1182 [923-1687] pg/mL), and progressive MCI group (MCI with progression to AD dementia during follow-up; 1336 [1061-1693] pg/mL) compared with control participants (1047 [809-1265] pg/mL) (P Conclusions and relevance Cerebrospinal fluid NFL concentration is increased by the early clinical stage of AD and is associated with cognitive deterioration and structural brain changes over time. 2 key findings →
Design: longitudinal study
Participants: 95
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
65/100
✓ Peer-reviewed
alzhub usefulness score 65 out of 100.
·
Neurology
·
2023-07-27
Choroid plexus (ChP) is emerging as a key brain structure in the pathophysiology of neurodegenerative disorders. 4 key findings →
Design: longitudinal study
Participants: 135
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
63/100
✓ Peer-reviewed
alzhub usefulness score 63 out of 100.
·
PharmacoEconomics
·
2024-11-01
Mean annual costs for individuals with clinically diagnosed AD were SEK 99,906, SEK 290,972, SEK 479,524, and SEK 795,617 in mild cognitive impairment (MCI), mild, moderate, and severe AD. 1 key finding →
Design: cohort
Participants: 95,853
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
We enrolled a cohort of 1070 PSEN1 E280A mutation carriers and 1074 non-carriers with baseline assessments; of these participants, longitudinal measures (with a mean follow-up of 6 years) were available for 242 mutation carriers and 262 non-carriers. 1 key finding →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
62/100
✓ Peer-reviewed
alzhub usefulness score 62 out of 100.
·
JAMA network open
·
2025-05-01
Lobar CMB counts and the presence of CAA were associated with downstream AD plasma biomarkers, including p-tau217 (β = 0.12 [95% CI, 0.05-0.18] and 0.29 [95% CI, 0.12-0.47], respectively), GFAP (β = 0.07 [95% CI, 0.03-0.12] and 0.20 [95% CI, 0.09-0.31], respectively), and NfL (β = 0.07 [95% CI, 0.03-0.11] and 0.16 [95% CI, 0.06-0.25], respectively) with and without the mediation of Aβ uptake on PET (indirect effect: lobar CMBs-p-tau217, 59.8% [β = 0.07 (95% CI, 0.03-0.11)]; lobar CMBs-GFAP, 49.3% [β = 0.04 (95% CI, 0.01-0.06)]; lobar CMBs-NfL, 20.9% [β = 0.01 (95% CI, 0.01-0.03)]; CAA-p-tau217, 50.9% [β = 0.15 (95% CI, 0.06-0.24)]; CAA-GFAP, 39.2% [β = 0.08 (95% CI, 0.03-0.13)]; CAA-NfL, 19.2% [β = 0.03 (95% CI, 0.01-0.05)]). 4 key findings →
Design: cohort study
Participants: 1,708
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
61/100
✓ Peer-reviewed
alzhub usefulness score 61 out of 100.
·
JAMA neurology
·
2017-01-01
These findings suggest amyloid pathologies significantly influence white matter and that these abnormalities may signify an early feature of the disease process. 4 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
60/100
✓ Peer-reviewed
alzhub usefulness score 60 out of 100.
·
JAMA network open
·
2023-11-01
These findings suggest that increases in certain plasma AD biomarkers are associated with NP in WLWH and WLWOH and may be associated with later onset of AD, and measuring these biomarkers could be a pivotal advancement in monitoring aging brain health and development of AD among women with and without HIV. 5 key findings →
Design: cohort study
Participants: 307
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
60/100
✓ Peer-reviewed
alzhub usefulness score 60 out of 100.
·
Nature aging
·
2022-11-28
The role of microglia in tau accumulation is currently unclear but could provide an important insight into the mechanisms underlying Alzheimer's disease (AD) 1 . 4 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
We investigated the effects of matrix type and reagent batch changes on diagnostic performances and longitudinal trajectories of brain-derived tau (BD-tau). 4 key findings →
Design: longitudinal study
Participants: 26
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Insulin, insulin-like growth factors (IGF) and their receptors are highly expressed in the adult hippocampus. 4 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
56/100
✓ Peer-reviewed
alzhub usefulness score 56 out of 100.
·
PharmacoEconomics
·
2026-04-01
This study estimated the utilization and lifetime costs of formal care for AD dementia using longitudinal register data. 4 key findings →
Design: cohort
Participants: 20,366
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
Changes in CSF biomarker levels may identify early neurodegenerative processes of Alzheimer disease. 2 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomized / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multicenter collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 32,580 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.